Sharpening Victoza's edge, Novo touts data in trial against Januvia, Byetta

Novo Nordisk ($NVO) racked up another set of positive data for its diabetes drug Victoza. The GLP-1 agonist bested Merck's ($MRK) Januvia and Amylin Pharmaceuticals' ($AMLN) Byetta once again, this time by helping more patients push their blood sugar levels below a target of 7%. The Danish drugmaker has been working to sharpen Victoza's edge in the fast-growing diabetes market. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.